Long-term benefits for women with breast cancer who take letrozole
13th Dec 2005, 14:35 GMT
New data from the MA-17 study have shown Femara® (letrozole) use led to a 69% reduction in risk of breast cancer returning, even years after completing standard tamoxifen therapy.
Long-term benefits for women with breast cancer who take letrozole related news:
- More good news - Femara helps prevent the return of breast cancer — News-Medical News Feed
- Aromatase inhibitor shows promise for breast cancer patients — The Cancer Blog
- Gene variation affects tamoxifen's benefit for breast cancer — EurekAlert! - Cancer
- More women will survive breast cancer with Arimidex (anastrozole) than tamoxifen — OnMedica Latest News
- New Clinical Data Show Dramatic Benefits of Femara for Women with Breast Cancer Even After Prolonged Period of No Anti-Cancer Treatment — Mammography News from StratCenter.com
- Silhouettes representing women with breast cancer. A major ... — Health Photos on Yahoo! News Photos
- Radiotherapy Improves 15-year Survival After Breast-conserving Surgery (lumpectomy) — Medical News Today RSS/XML Feed
- Breast cancer risk higher in young smokers (Reuters) — Yahoo! News: Health News
- Taking Hormonal Therapy Right to Prevent Recurrence — Breast Cancer Chronicles
- Women With Breast Cancer Risk Developing Other Cancers — VOA News: Health
Latest news from OnMedica Latest News:
- Diagnosis by internet now popular and can work
- Draft NICE guidance on substance misuse available for consultation
- MDU advise on healthcare assitants giving flu vaccinations
- Drinking not recognised as mouth cancer cause
- More confusion over painkillers revealed
- New sexual health campaign for young adults
- NHS financial crisis is squeezing medical education
- World Diabetes Day is today
- NHS patients to choose hospitals through local libraries
- Patient hospital choice system needs improvement